1446236-31-2

Basic information

• Product Name: (3-bromo-4-(2,4-difluorophenoxy)benzyl)(ethyl)sulfane
• Synonyms: (3-bromo-4-(2,4-difluorophenoxy)benzyl)(ethyl)sulfane
• CAS NO: 1446236-31-2
• Molecular Weight: 359.234
• Mol File: 1446236-31-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (3-bromo-4-(2,4-difluorophenoxy)benzyl)(ethyl)sulfane(CAS DataBase Reference)
• NIST Chemistry Reference: (3-bromo-4-(2,4-difluorophenoxy)benzyl)(ethyl)sulfane(1446236-31-2)
• EPA Substance Registry System: (3-bromo-4-(2,4-difluorophenoxy)benzyl)(ethyl)sulfane(1446236-31-2)

Safety Data

• Hazardous Substances Data: 1446236-31-2(Hazardous Substances Data)

Upstream product

• 77771-02-9 3-bromo-4-fluorobenzaldehyde 
• 811-51-8 sodium thioethylate 

Downstream Products

• 1446236-33-4 4-(2-(2,4-difluorophenoxy)-5-(ethylsulfonylmethyl)phenyl)-6-methyl-1-tosyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one 
• 1446235-30-8 4-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)methyl]phenyl}-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 

Relevant articles and documents

Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2 H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitors

The bromodomain and extra-terminal (BET) family proteins have recently emerged as promising drug targets for cancer therapy. In this study, identification of an 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one fragment (47) as a new binder to the BET bromodomains

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

The development of bromodomain and extraterminal domain (BET) bromodomain inhibitors and their examination in clinical studies, particularly in oncology settings, has garnered substantial recent interest. An effort to generate novel BET bromodomain inhibi

BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).